Display options
Cite
Al Ahmad A, Paffrath V, Clima R, et al. Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091298.
Al Ahmad, A., Paffrath, V., Clima, R., Busch, J. F., Rabien, A., Kilic, E., Villegas, S., Timmermann, B., Attimonelli, M., Jung, K., & Meierhofer, D. (2019). Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation. Cancers, 11(9), . https://doi.org/10.3390/cancers11091298
Al Ahmad, Ayham, et al. "Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091298
Al Ahmad A, Paffrath V, Clima R, Busch JF, Rabien A, Kilic E, Villegas S, Timmermann B, Attimonelli M, Jung K, Meierhofer D. Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation. Cancers (Basel). 2019 Sep 03;11(9). doi: 10.3390/cancers11091298. PMID: 31484429; PMCID: PMC6770591.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Sep 03;11(9). doi: 10.3390/cancers11091298.

Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation.

Cancers

Ayham Al Ahmad, Vanessa Paffrath, Rosanna Clima, Jonas Felix Busch, Anja Rabien, Ergin Kilic, Sonia Villegas, Bernd Timmermann, Marcella Attimonelli, Klaus Jung, David Meierhofer

Affiliations

  1. Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Ihnestrasse 63-73, 14195 Berlin, Germany. [email protected].
  2. Fachbereich Biologie, Chemie, Pharmazie, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany. [email protected].
  3. Berlin Institute for Urologic Research, Charitéplatz 1, 10117 Berlin, Germany. [email protected].
  4. Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Ihnestrasse 63-73, 14195 Berlin, Germany. [email protected].
  5. Berlin Institute for Urologic Research, Charitéplatz 1, 10117 Berlin, Germany. [email protected].
  6. Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Via E.Orabona, 470126 Bari, Italy. [email protected].
  7. Department of Medical and Surgical Sciences-DIMEC, Medical Genetics Unit, University of Bologna, 40126 Bologna, Italy. [email protected].
  8. Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. [email protected].
  9. Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. [email protected].
  10. Institut für Pathologie am Klinikum Leverkusen, Am Gesundheitspark 11, 51375 Leverkusen, Germany. [email protected].
  11. Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. [email protected].
  12. Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. [email protected].
  13. Max Planck Institute for Molecular Genetics, Sequencing Core Facility, Ihnestrasse 63-73, 14195 Berlin, Germany. [email protected].
  14. Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Via E.Orabona, 470126 Bari, Italy. [email protected].
  15. Berlin Institute for Urologic Research, Charitéplatz 1, 10117 Berlin, Germany. [email protected].
  16. Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. [email protected].
  17. Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Ihnestrasse 63-73, 14195 Berlin, Germany. [email protected].

PMID: 31484429 PMCID: PMC6770591 DOI: 10.3390/cancers11091298

Abstract

Papillary renal cell carcinoma (pRCC) is a malignant kidney cancer with a prevalence of 7-20% of all renal tumors. Proteome and metabolome profiles of 19 pRCC and patient-matched healthy kidney controls were used to elucidate the regulation of metabolic pathways and the underlying molecular mechanisms. Glutathione (GSH), a main reactive oxygen species (ROS) scavenger, was highly increased and can be regarded as a new hallmark in this malignancy. Isotope tracing of pRCC derived cell lines revealed an increased de novo synthesis rate of GSH, based on glutamine consumption. Furthermore, profound downregulation of gluconeogenesis and oxidative phosphorylation was observed at the protein level. In contrast, analysis of the The Cancer Genome Atlas (TCGA) papillary RCC cohort revealed no significant change in transcripts encoding oxidative phosphorylation compared to normal kidney tissue, highlighting the importance of proteomic profiling. The molecular characteristics of pRCC are increased GSH synthesis to cope with ROS stress, deficient anabolic glucose synthesis, and compromised oxidative phosphorylation, which could potentially be exploited in innovative anti-cancer strategies.

Keywords: Papillary renal cell carcinoma (pRCC); glutathione metabolism; metabolic reprogramming; metabolome profiling; proteome profiling

Conflict of interest statement

The authors declare no competing interests.

References

  1. Front Physiol. 2018 Jul 13;9:902 - PubMed
  2. J Proteome Res. 2015 Jan 2;14(1):224-35 - PubMed
  3. J Biol Chem. 2006 Jun 16;281(24):16768-76 - PubMed
  4. Cell Rep. 2016 Mar 15;14(10):2476-89 - PubMed
  5. Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9 - PubMed
  6. Physiol Rev. 2016 Jul;96(3):1071-91 - PubMed
  7. Hum Genet. 2016 Jan;135(1):121-36 - PubMed
  8. N Engl J Med. 2016 Jan 14;374(2):135-45 - PubMed
  9. Carcinogenesis. 2004 Jun;25(6):1005-10 - PubMed
  10. Nature. 2012 Nov 15;491(7424):364-73 - PubMed
  11. Mod Pathol. 1997 Jun;10(6):537-44 - PubMed
  12. Nature. 2014 Sep 11;513(7517):251-5 - PubMed
  13. Nat Rev Cancer. 2018 Jan;18(1):51-63 - PubMed
  14. Mol Cancer Res. 2016 Jul;14(7):589-98 - PubMed
  15. Ther Clin Risk Manag. 2017 Feb 27;13:279-285 - PubMed
  16. Cell Death Discov. 2015 Sep 07;1:15016 - PubMed
  17. Dtsch Arztebl Int. 2016 Sep 5;113(35-36):590-6 - PubMed
  18. J Agric Food Chem. 2010 Aug 25;58(16):9273-80 - PubMed
  19. Proc Natl Acad Sci U S A. 1966 Oct;56(4):1275-82 - PubMed
  20. Clin Cancer Res. 2008 Apr 15;14(8):2270-5 - PubMed
  21. Integr Cancer Ther. 2018 Jun;17(2):210-216 - PubMed
  22. Mol Carcinog. 2014 Feb;53(2):138-44 - PubMed
  23. Biochem J. 2015 Dec 1;472(2):225-37 - PubMed
  24. Cell Metab. 2018 Jun 05;27(6):1249-1262.e4 - PubMed
  25. Nucleic Acids Res. 2013 Jan;41(Database issue):D808-15 - PubMed
  26. Biochim Biophys Acta. 2006 Mar;1760(3):380-7 - PubMed
  27. Oncotarget. 2017 Nov 11;8(62):105882-105904 - PubMed
  28. Nat Biotechnol. 2008 Dec;26(12):1367-72 - PubMed
  29. Int J Oncol. 2008 Oct;33(4):725-31 - PubMed
  30. Cancer Discov. 2017 Oct;7(10):1069-1087 - PubMed
  31. J Clin Oncol. 2017 Sep 10;35(26):2981-2983 - PubMed
  32. Sci Rep. 2017 Jul 20;7(1):6069 - PubMed
  33. J Cell Biochem. 2000 Apr;78(1):62-72 - PubMed
  34. Free Radic Res. 2008 Aug;42(8):689-706 - PubMed
  35. Cell Rep. 2018 Apr 3;23(1):313-326.e5 - PubMed
  36. J Biol Chem. 2004 Mar 5;279(10):8732-9 - PubMed
  37. Cancer Res. 2017 Dec 1;77(23):6746-6758 - PubMed
  38. Nature. 2017 Aug 3;548(7665):112-116 - PubMed
  39. Oncogene. 2009 Oct 22;28(42):3689-701 - PubMed
  40. Adv Cancer Res. 2014;122:69-101 - PubMed
  41. Int J Mol Sci. 2019 Jul 26;20(15):null - PubMed
  42. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  43. Nihon Kyobu Geka Gakkai Zasshi. 1992 Mar;40(3):382-6 - PubMed
  44. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6283-E6290 - PubMed
  45. Eur Radiol. 2017 Nov;27(11):4866-4873 - PubMed
  46. PLoS Genet. 2017 Mar 30;13(3):e1006685 - PubMed
  47. J Clin Oncol. 2005 Apr 20;23(12):2763-71 - PubMed
  48. Biochim Biophys Acta. 2013 May;1830(5):3143-53 - PubMed
  49. Bioinformatics. 2014 Nov 1;30(21):3115-7 - PubMed
  50. Oncol Rep. 2018 Jun;39(6):2996-3006 - PubMed
  51. Mol Cancer. 2016 Dec 19;15(1):83 - PubMed
  52. Clin Cancer Res. 2009 Feb 15;15(4):1162-9 - PubMed
  53. J Cancer. 2017 Apr 9;8(7):1197-1204 - PubMed
  54. Biol Chem. 2008 Aug;389(8):983-91 - PubMed
  55. Mol Cell Proteomics. 2016 May;15(5):1728-39 - PubMed
  56. Cell. 2018 Apr 5;173(2):291-304.e6 - PubMed
  57. Onco Targets Ther. 2016 Oct 07;9:6099-6109 - PubMed
  58. Cell Metab. 2014 Sep 2;20(3):526-40 - PubMed
  59. J Biol Chem. 2007 Aug 24;282(34):24495-503 - PubMed
  60. J Biol Chem. 2015 Feb 6;290(6):3680-92 - PubMed
  61. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6274-E6282 - PubMed
  62. Breast Cancer Res Treat. 2012 Feb;131(3):791-800 - PubMed
  63. Nat Methods. 2016 Sep;13(9):731-40 - PubMed
  64. Nat Rev Urol. 2014 Aug;11(8):465-75 - PubMed
  65. Cell Physiol Biochem. 2017;42(1):397-406 - PubMed
  66. Urology. 2013 Oct;82(4):840-5 - PubMed
  67. Diabetes Care. 2001 Feb;24(2):382-91 - PubMed
  68. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10684-9 - PubMed
  69. Eur Urol Focus. 2019 Jul;5(4):608-618 - PubMed
  70. Head Neck. 2013 Oct;35(10):1475-81 - PubMed

Publication Types